Physician profile
John A Kyncl
NPI 1023001518
$8,761.68
in general payments reported to CMS, 2019-2025
28 companies · $2,077 in 2025
The $2,077 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,873 · 2020: $811 · 2021: $1,233 · 2022: $390 · 2023: $509 · 2024: $869 · 2025: $2,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,454.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,734.51 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,361.59 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,197.48 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $913.98 | 2019-2024 | Mounjaro |
| Pfizer INC. | $562.92 | 2019-2025 | |
| Boston Scientific Corporation | $422.28 | 2019-2020 | |
| Corcept Therapeutics | $366.97 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $353.85 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $317.40 | 2019 | |
| Amgen INC. | $265.50 | 2019-2023 | Otezla, Repatha |
| Abbott Laboratories | $235.04 | 2024-2025 | Freestyle Libre 3 |
| Philips North America LLC | $158.29 | 2023-2025 | (Ak6) Vest Therapy, Vest Therapy Und, Disposable Vest |
| Avanir Pharmaceuticals, INC. | $125.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $123.71 | 2021 | |
| Abbvie INC. | $99.80 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $90.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $81.44 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $75.75 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $41.68 | 2025 | |
| Recordati_rare_diseases_inc. | $40.96 | 2025 | Isturisa |
| Exact Sciences Corporation | $38.66 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amarin Pharma, INC. | $29.20 | 2019 | |
| Janssen Biotech, INC. | $28.77 | 2019 | |
| Akcea Therapeutics, INC. | $27.02 | 2019-2020 | |
| Glaxosmithkline, LLC. | $19.94 | 2019 | |
| Ethicon US, LLC | $19.33 | 2019 | |
| Esperion Therapeutics, INC. | $16.67 | 2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $13.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kyncl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.